Oncolytic adenoviruses as a therapeutic approach for osteosarcoma: A new hope.
Oncolytic adenoviruses as a therapeutic approach for osteosarcoma: A new hope.
复制标题
DOI：
10.1016/j.jbo.2016.12.001
复制
发表时间：
2017-11
影响因子：
3.4
通讯作者：
Alonso MM
中科院分区：
文献类型：
--
作者：
Garcia-Moure M;Martinez-Vélez N;Patiño-García A;Alonso MM
骨肉瘤是最常见的非血液来源的骨癌，主要影响儿童患者。在过去的50年里，外科手术的改进，以及积极的新辅助和辅助化疗鸡尾酒的引入，使这些患者的生存率提高到近70%。尽管最初的治疗进展，但在过去的三十年里，骨肉瘤的治疗并没有得到实质性的改善，几乎30%的患者在标准治疗后没有反应或复发。对于这一群体，迫切需要实施新的治疗方法。溶瘤腺病毒是有条件复制的病毒，其被工程化以选择性地在肿瘤细胞中复制并杀死肿瘤细胞，同时在健康细胞中保持静止。在过去的几年里，已经有多个临床前和临床研究使用这些病毒作为治疗剂在治疗广泛的癌症，包括骨肉瘤。在这篇综述中，我们总结了一些最相关的文献中使用溶瘤腺病毒治疗人骨肉瘤肿瘤的皮下，原位和转移性小鼠模型。总之，迄今为止，溶瘤腺病毒的临床前研究已证明其对局部和转移性骨肉瘤安全有效。在其他肿瘤中使用溶瘤腺病毒进行的I/II期临床试验所获得的知识表明，病毒有可能唤醒患者自身的免疫系统，产生对肿瘤的反应。生成骨肉瘤免疫活性腺病毒友好模型将允许更好地理解这种潜力。未来溶瘤腺病毒治疗骨肉瘤的临床试验是必要的。
Osteosarcoma is the most common bone cancer among those with non-hematological origin and affects mainly pediatric patients. In the last 50 years, refinements in surgical procedures, as well as the introduction of aggressive neoadjuvant and adjuvant chemotherapeutic cocktails, have increased to nearly 70% the survival rate of these patients. Despite the initial therapeutic progress the fight against osteosarcoma has not substantially improved during the last three decades, and almost 30% of the patients do not respond or recur after the standard treatment. For this group there is an urgent need to implement new therapeutic approaches. Oncolytic adenoviruses are conditionally replicative viruses engineered to selectively replicate in and kill tumor cells, while remaining quiescent in healthy cells. In the last years there have been multiple preclinical and clinical studies using these viruses as therapeutic agents in the treatment of a broad range of cancers, including osteosarcoma. In this review, we summarize some of the most relevant published literature about the use of oncolytic adenoviruses to treat human osteosarcoma tumors in subcutaneous, orthotopic and metastatic mouse models. In conclusion, up to date the preclinical studies with oncolytic adenoviruses have demonstrated that are safe and efficacious against local and metastatic osteosarcoma. Knowledge arising from phase I/II clinical trials with oncolytic adenoviruses in other tumors have shown the potential of viruses to awake the patient´s own immune system generating a response against the tumor. Generating osteosarcoma immune-competent adenoviruses friendly models will allow to better understand this potential. Future clinical trials with oncolytic adenoviruses for osteosarcoma tumors are warranted.
登录
查看更多内容
影响因子：
37.3
作者：
Graat, Harm C. A.;van Beusechem, Victor W.;Wuisman, Paul I. J. M.
通讯作者：
Wuisman, Paul I. J. M.
影响因子：
5.4
作者：
Harada, JN;Berk, AJ
通讯作者：
Berk, AJ
影响因子：
4.2
作者：
Ayerza, Miguel A.;Farfalli, German L.;Luis Muscolo, D.
通讯作者：
Luis Muscolo, D.
影响因子：
14.9
作者：
ARROYO, M;RAYCHAUDHURI, P
通讯作者：
RAYCHAUDHURI, P
影响因子：
64.8
作者：
BANDARA, LR;LATHANGUE, NB
通讯作者：
LATHANGUE, NB